Cargando…

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy

BACKGROUND: The purpose of this research was to compare the effects of niacin extended-release in combination with simvastatin (NER/S) versus atorvastatin monotherapy on high-density lipoprotein (HDL) particle number and size in patients with hyperlipidemia or dyslipidemia from the SUPREME study. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toth, Peter P, Thakker, Kamlesh M, Jiang, Ping, Padley, Robert J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273410/ https://www.ncbi.nlm.nih.gov/pubmed/22323895 http://dx.doi.org/10.2147/VHRM.S22601

Ejemplares similares

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
por: Insull, William, et al.
Publicado: (2010)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Effect of niacin monotherapy on high density lipoprotein composition and function
por: Gordon, Scott M., et al.
Publicado: (2020)

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
por: Robinson, Jennifer G
Publicado: (2009)

Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
por: Lyseng-Williamson, Katherine A.
Publicado: (2012)

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients
por: Yadav, Rahul, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
por: Guyton, John R., et al.
Publicado: (2012)

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
por: Michailov, Galin V., et al.
Publicado: (2011)

The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a)
por: Helmbold, Alan F., et al.
Publicado: (2010)

Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome
por: Chow, Dominic C, et al.
Publicado: (2008)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
por: Farnier, Michel, et al.
Publicado: (2014)

Hypophosphatemic effect of niacin extended release in ischemic kidney disease
por: Yasmeen, Ghazala, et al.
Publicado: (2015)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Atorvastatin and simvastatin as analgesic agents in experimental models
por: Dwajani, S., et al.
Publicado: (2012)

Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers
por: Zhang, Pingping, et al.
Publicado: (2015)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Atorvastatin and simvastatin protects cognitive impairment in an animal model of sepsis
por: Alexandre, Pedro CB, et al.
Publicado: (2013)

Experimental evaluation of analgesic and anti-inflammatory activity of simvastatin and atorvastatin
por: Jaiswal, Swapnil R., et al.
Publicado: (2012)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
por: Hu, Miao, et al.
Publicado: (2015)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
por: Masadeh, Majed, et al.
Publicado: (2012)

Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk
por: Cho, Yun-Kyeong, et al.
Publicado: (2011)

CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2015)

Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand
por: Rattanachotphanit, Thananan, et al.
Publicado: (2019)

Pregnancy is accompanied by larger high density lipoprotein particles and compositionally distinct subspecies
por: Melchior, John T., et al.
Publicado: (2021)

Niacin in Maize
por: Burkholder, Paul R., et al.
Publicado: (1944)

Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
por: Bays, Harold E, et al.
Publicado: (2015)

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
por: Ong, Kwok Leung, et al.
Publicado: (2018)

Effect of Niacin on Carotid Atherosclerosis in Patients at Low-Density Lipoprotein-Cholesterol Goal but High Lipoprotein (a) Level: a 2-Year Follow-Up Study
por: Song, Shinjeong, et al.
Publicado: (2019)

Evaluating the Release of Different Commercial Orally Modified Niacin Formulations In Vitro
por: Chbib, Christiane, et al.
Publicado: (2023)

Effect of Simvastatin and Atorvastatin on Serum Vitamin D and Bone Mineral Density in Hypercholesterolemic Patients: A Cross-Sectional Study
por: Thabit, K. Abrar, et al.
Publicado: (2014)

Larger Testicular Volume Is Independently Associated with Favorable Indices of Lung Function
por: Kim, Tae Beom, et al.
Publicado: (2017)

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

Evaluation of Sexual Dimorphism in the Efficacy and Safety of Simvastatin/Atorvastatin Therapy in a Southern Brazilian Cohort
por: Smiderle, Lisiane, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qs7vim7f0btmkc3obfqk37j844